ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.
Company Size
51-200
Company Stage
Early VC
Total Funding
$175M
Headquarters
Los Altos, California
Founded
2021
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?